Eidos, Avrobio shoot for $201M as biotech IPOs continue to roll forward on Nasdaq
Just a few weeks after RA Capital’s high-profile partner Rajeev Shah signed up to lead a $64 million round for San Francisco-based Eidos Therapeutics, BridgeBio’s startup focused on TTR amyloidosis, the biotech is out of the IPO chute in search of $115 million or more. And they are right on the heels of another startup on the East Coast, Avrobio, joining the latest wave of new arrivals to try their luck and science on Wall Street.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.